CJC-1295 is a research-grade peptide supplied strictly for in-vitro and laboratory research use only. It is not for human or animal consumption, is not a dietary supplement, is not an FDA-approved drug, and is prohibited in sport by the World Anti-Doping Agency. This profile is third-person science education describing what CJC-1295 is and what researchers measure when they study it in growth-hormone-axis models. Nothing here is medical, dosing, or administration guidance, and nothing implies any reader should acquire or use the compound.
What CJC-1295 Is
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), the hypothalamic signaling peptide that instructs the pituitary gland to synthesize and release growth hormone. In research models it is studied as a molecular tool for probing the top of the growth-hormone axis, meaning the upstream control point where GH secretion is initiated rather than where its downstream effects are carried out. It is a laboratory reference material, not a product intended for use in people or animals.
The molecule is built on the first 29 amino acids of native GHRH, the fragment that retains the receptor-activating portion of the full hormone. Native GHRH is degraded within minutes in biological systems, which historically limited its usefulness as a research probe. CJC-1295 was engineered to resist that rapid breakdown, giving investigators a more stable tool for studying sustained GHRH-receptor engagement. For foundational background on peptide structure and signaling, see what peptides are.
Because CJC-1295 acts upstream, the growth hormone it elicits in research models remains subject to the body's natural feedback controls, chiefly the braking hormone somatostatin. This is a defining feature that distinguishes GHRH-analog research tools from compounds that bypass or override those controls, and it shapes how investigators interpret any GH measurement they collect.
The GHRH Receptor and the Growth-Hormone Axis
To understand CJC-1295, a researcher first has to understand the system it acts on. The growth-hormone axis, formally the hypothalamic-pituitary-somatotropic axis, is governed by two opposing hypothalamic signals. GHRH stimulates the pituitary somatotroph cells to produce and release growth hormone, while somatostatin suppresses that release. The amount of GH present at any moment reflects the balance between these two competing inputs.
CJC-1295 binds the GHRH receptor on the somatotroph, the same receptor the body's own GHRH uses. Activating that receptor in research models promotes GH synthesis and pulsatile release. Because the compound works through the native receptor rather than an artificial pathway, the GH pulses it produces still rise and fall under the influence of somatostatin tone, which investigators treat as an important interpretive constraint.
- GHRH: hypothalamic peptide that stimulates GH synthesis and release from the pituitary.
- Somatostatin: the opposing hypothalamic signal that suppresses GH release.
- Somatotroph: the pituitary cell type that produces growth hormone.
- GHRH receptor: the target CJC-1295 engages to model upstream GH-axis stimulation.
The DAC vs Non-DAC Distinction
The single most important structural detail in the CJC-1295 research literature is whether the molecule carries a Drug Affinity Complex, abbreviated DAC. This distinction defines two very different research tools that share a name, and confusing them is one of the most common errors in the informal discussion of this compound.
The DAC variant includes a chemical group that binds covalently to serum albumin, a long-lived carrier protein in the blood. In research models this albumin binding dramatically extends the time the peptide remains present, prolonging elevated GH and insulin-like growth factor 1 (IGF-1) markers over a window measured in days rather than minutes. This sustained-elevation profile is what makes the DAC version distinctive as a research probe.
The non-DAC variant, frequently labeled modified GRF 1-29 or CJC-1295 without DAC, lacks that albumin-binding group. It is stabilized against the fastest degradation pathways but is studied for a much shorter, more pulse-like activity profile that more closely resembles the natural rhythm of GHRH signaling. Researchers choose between the two depending on whether they want to model chronic or pulsatile receptor engagement.
Why the Distinction Changes the Experiment
A study designed around sustained GH elevation and one designed around discrete GH pulses ask fundamentally different questions, so the DAC status is not a trivial labeling detail. It determines the pharmacokinetic shape of the exposure, the appropriate sampling schedule, and how the data should be compared against other secretagogues. Reporting a CJC-1295 result without specifying DAC status makes the finding difficult to reproduce or interpret.
Mechanism Studied in Preclinical Models
In preclinical and in-vitro research, CJC-1295 is examined for how GHRH-receptor activation translates into measurable GH output and downstream IGF-1 production. When GH reaches the liver and peripheral tissues, it stimulates IGF-1 synthesis, and IGF-1 carries much of the anabolic signal studied in growth research. Investigators therefore track both the immediate GH response and the slower IGF-1 response as complementary readouts.
A property researchers emphasize is that GHRH analogs preserve the pulsatile character of GH release rather than flattening it into a constant level. Pulsatility is biologically meaningful because many GH-responsive processes are sensitive to the pattern of exposure, not just the total amount. CJC-1295 with DAC is studied specifically because it raises the baseline around which those pulses occur, letting investigators separate tonic from pulsatile contributions in model systems.
The CJC-1295 and Ipamorelin Pairing
The most frequently studied combination involving CJC-1295 pairs it with ipamorelin, a selective ghrelin-mimetic peptide. The rationale rests on the dual-pathway structure of the GH axis. CJC-1295 drives the GHRH receptor, while ipamorelin drives a separate receptor, the growth-hormone secretagogue receptor (GHS-R1a). Because the two act through non-competing pathways, researchers study whether stimulating both at once produces an additive or a synergistic GH response.
In research models, ipamorelin also reduces somatostatin tone, which can amplify the GH pulse that a GHRH signal from CJC-1295 initiates. Ipamorelin selectivity keeps confounding hormone markers such as cortisol and prolactin low, so the GH signal is easier to isolate. This makes the pairing a textbook illustration of complementary-pathway experimental design. For the mechanistic background on both receptor systems, see the growth-hormone secretagogues guide and the ipamorelin research reference.
This pairing is described here strictly as a mechanism researchers investigate, never as a protocol. The combination is discussed in the literature to answer a scientific question about receptor convergence, and its presence on this page is educational context about experimental design.
Pharmacokinetic Properties Researchers Examine
Half-life is a central variable in CJC-1295 research because it is the property the molecule was engineered to modify. The DAC variant extended half-life in research models is attributed to albumin binding, which shields the peptide from renal clearance and enzymatic degradation. Investigators study how this extended presence reshapes the GH and IGF-1 response curves compared with native GHRH or the non-DAC variant.
Other pharmacokinetic questions include how quickly receptor activation begins, how long IGF-1 markers remain elevated after a single exposure in a model, and whether repeated exposure alters the receptor responsiveness over time. These are standard characterization questions for any secretagogue research tool, and answering them accurately depends entirely on knowing the precise identity and purity of the material used.
What Researchers Measure
CJC-1295 research is organized around defined, reproducible endpoints rather than subjective impressions. Because the compound sits at the top of the GH axis, the measurements focus on the cascade it initiates and on the fidelity of the experimental system itself.
- Growth hormone concentration in the model system after exposure.
- IGF-1 concentration as the downstream marker of GH-axis activation.
- The temporal pattern of GH release, including pulse amplitude and baseline.
- Receptor-binding characteristics at the GHRH receptor.
- Identity and purity of the reference material, confirmed before any experiment.
Why Purity and a Certificate of Analysis Matter
In peptide research, a result is only as trustworthy as the compound that produced it. A preparation contaminated with truncated sequences, synthesis byproducts, residual solvents, or endotoxins can confound every downstream measurement and make a study impossible to reproduce. For a GHRH analog, where the DAC modification itself must be verified, identity confirmation is especially important because a mislabeled variant would invalidate the entire experimental premise.
A Certificate of Analysis (COA) documents what analytical testing confirmed about a specific lot. A meaningful COA reports identity, typically by mass spectrometry, and purity, typically by high-performance liquid chromatography (HPLC) expressed as a main-peak percentage, and it ties those results to a lot number that matches the physical vial. That chain of identity is what lets one experiment be compared meaningfully against another. Peptides Factory Direct documents identity and purity for its research-use-only catalog; to review procurement terms, see order.
- Identity confirmation by mass spectrometry, including verification of DAC status.
- Purity by HPLC, reported as a main-peak percentage.
- Residual solvent and endotoxin or microbial testing where applicable.
- Lot number matching the physical vial for batch traceability.
Regulatory and Compliance Context
Stating the regulatory category plainly is part of responsible science communication. CJC-1295 is a research chemical supplied for laboratory and in-vitro use only. It is not a dietary supplement, is not approved by the FDA as a drug, and is not intended for human or animal consumption. Any question about human health, treatment, or growth-related conditions belongs with a licensed clinician, not with a research-chemical purchase.
CJC-1295, like other GHRH analogs and growth-hormone secretagogues, is prohibited in sport by the World Anti-Doping Agency under the category of peptide hormones, growth factors, and related substances. This is stated as factual regulatory context for researchers, not as guidance toward or away from any activity. Anyone handling the material in a legitimate research setting is responsible for complying with the laws and institutional rules that apply to their jurisdiction. For related research questions, see growth-hormone peptide questions, the growth-hormone peptides category overview, and the broader guide to peptides studied in muscle-growth research.
Create a free research account to view current pricing and bundles and place an order.
Frequently asked questions
What is CJC-1295 in a research context?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) studied as a laboratory tool for the top of the growth-hormone axis. In research models it binds the GHRH receptor on pituitary cells and stimulates growth hormone synthesis and release. It is a research-use-only reference material, not a medicine, supplement, or product for human or animal consumption, and it is studied to generate data rather than outcomes in people.
What is the difference between CJC-1295 with DAC and without DAC?
The Drug Affinity Complex (DAC) is a chemical group that binds serum albumin and, in research models, greatly extends how long the peptide remains present, sustaining elevated growth hormone and IGF-1 markers over days. The non-DAC variant, often called modified GRF 1-29, lacks that group and is studied for a shorter, more pulse-like profile. The distinction defines two different research tools and must be specified for a result to be reproducible.
How does CJC-1295 differ from a GHRP like ipamorelin?
CJC-1295 is a GHRH analog that binds the GHRH receptor, working through the same pathway as the body's own GHRH. Ipamorelin is a ghrelin mimetic that binds a different receptor, GHS-R1a, and also reduces somatostatin tone. Because they act on separate receptors, researchers study them as complementary tools rather than interchangeable ones, and the two are frequently examined together to probe dual-pathway stimulation of the axis.
Why are CJC-1295 and ipamorelin studied together?
The pairing reflects the dual-pathway structure of the growth-hormone axis. CJC-1295 stimulates the GHRH receptor while ipamorelin stimulates the separate GHS-R1a receptor, so the two drive growth hormone release through non-competing mechanisms. In research models this can produce a response greater than either alone, and ipamorelin selectivity keeps confounding hormone markers low. It is presented as a studied mechanism of receptor convergence, not as a protocol.
What does CJC-1295 do to IGF-1 in research models?
When CJC-1295 stimulates growth hormone release, that growth hormone reaches the liver and peripheral tissues and promotes the synthesis of insulin-like growth factor 1 (IGF-1). Researchers track IGF-1 as the downstream marker of growth-hormone-axis activation, alongside the immediate growth hormone response. Both readouts are measured in laboratory model systems only, and they characterize the compound's mechanism rather than any effect in a person.
Is CJC-1295 approved by the FDA?
No. CJC-1295 is a research chemical supplied strictly for laboratory and in-vitro use. It is not approved by the FDA as a drug, is not a dietary supplement, and is not intended for human or animal consumption. It is also prohibited in sport by the World Anti-Doping Agency. Any question about human health or treatment should be directed to a licensed clinician, not resolved through a research-chemical purchase.
Why does the half-life of CJC-1295 matter to researchers?
Half-life is the property the DAC variant was engineered to modify, so it is central to the compound's characterization. The extended half-life attributed to albumin binding reshapes the growth hormone and IGF-1 response curves compared with native GHRH, which acts over minutes. Investigators study these pharmacokinetic differences to understand how sustained versus pulsatile receptor engagement influences the axis in model systems.
Why is a Certificate of Analysis important for CJC-1295?
A Certificate of Analysis establishes that the material is what it claims to be and is pure enough to produce trustworthy data. For CJC-1295 this includes confirming the DAC status, because a mislabeled variant would invalidate the experiment. A meaningful COA reports identity by mass spectrometry and purity by HPLC, tied to a lot number matching the physical vial. Without that documentation, a research finding cannot be confidently attributed to the intended molecule.
All guides · Order research peptides
External references: U.S. Food and Drug Administration · Peptide (Wikipedia)